- $662.30m
- $251.53m
Brief: Olema Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Olema Pharmaceuticals Inc - Terminates ATM Prospectus For Common Stock Dated January 6, 2025 - SEC Filing
Olema Pharma Q3 net loss widens
Brief: Olema Pharmaceuticals Q3 Net Income USD -42.217 Million
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Olema Oncology Announces New Clinical Trial Agreement With Pfizer To Combine Palazestrant With Atirmociclib In Er+/Her2- Metastatic Breast Cancer
U.S. RESEARCH ROUNDUP- Advanced Drainage Systems, Assurant, Chipotle Mexican Grill
Olema Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Olema Pharma Q2 net loss widens to $43.8 mln
Olema Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Olema Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule
Olema Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Olema Oncology Q1 Net Income USD -30.389 Million
Olema Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Olema Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Olema Oncology Q4 Net Income USD -33.567 Million
Olema Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)